WS19.6 Impact of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) triple combination therapy on health-related quality of life (HRQoL) in people with cystic fibrosis (pwCF) homozygous for F508del (F/F): results from a Phase 3 clinical study

Journal of Cystic Fibrosis(2020)

Cited 1|Views49
No score
Key words
cystic fibrosis,triple combination therapy,hrqol,elexacaftor/tezacaftor/ivacaftor,health-related
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined